10x Genomics, Inc. (NASDAQ:TXG) insider Bradford Crutchfield sold 17,000 shares of 10x Genomics stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $174.49, for a total transaction of $2,966,330.00. Following the sale, the insider now directly owns 60,336 shares in the company, valued at $10,528,028.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Bradford Crutchfield also recently made the following trade(s):
- On Monday, July 12th, Bradford Crutchfield sold 17,000 shares of 10x Genomics stock. The shares were sold at an average price of $186.53, for a total transaction of $3,171,010.00.
Shares of NASDAQ TXG opened at $159.99 on Friday. The company has a market capitalization of $17.74 billion, a P/E ratio of -33.82 and a beta of 1.27. 10x Genomics, Inc. has a 52-week low of $115.39 and a 52-week high of $208.99. The company’s 50 day moving average price is $173.58 and its 200-day moving average price is $176.56.
Several institutional investors have recently added to or reduced their stakes in TXG. KB Financial Partners LLC acquired a new position in shares of 10x Genomics during the 1st quarter valued at $26,000. Benjamin Edwards Inc. acquired a new position in shares of 10x Genomics during the 1st quarter valued at $29,000. Alpha DNA Investment Management LLC lifted its position in shares of 10x Genomics by 481.8% during the 1st quarter. Alpha DNA Investment Management LLC now owns 192 shares of the company’s stock valued at $34,000 after acquiring an additional 159 shares during the period. Tsfg LLC acquired a new position in shares of 10x Genomics during the 2nd quarter valued at $37,000. Finally, Newfound Research LLC acquired a new position in shares of 10x Genomics during the 2nd quarter valued at $42,000. Institutional investors own 69.62% of the company’s stock.
Several equities research analysts recently commented on TXG shares. Bank of America downgraded shares of 10x Genomics from a “buy” rating to a “neutral” rating and set a $180.00 target price on the stock. in a research report on Tuesday. Zacks Investment Research downgraded shares of 10x Genomics from a “hold” rating to a “sell” rating in a research report on Saturday, August 7th. Citigroup cut their target price on shares of 10x Genomics from $240.00 to $220.00 and set a “buy” rating on the stock in a research report on Thursday, August 5th. Finally, National Bank Financial started coverage on shares of 10x Genomics in a research report on Thursday. They set a “sector perform” rating and a $24.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. According to MarketBeat, 10x Genomics presently has a consensus rating of “Hold” and a consensus price target of $177.80.
About 10x Genomics
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
Further Reading: Initial Coin Offering (ICO)
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.